RxDoctor Payments Data

Venkat Chitumalla, MD

Nephrology · Ocala, FLNPI 1750585113

Payments from drug & device makers

$11,988in general payments, 2019–2025

Across 149 payments — averaging $80.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$8K
  • AstraZeneca$561
  • Amgen$506
  • Mallinckrodt Hospital Products Inc.$360
  • Mallinckrodt Enterprises LLC$327
  • Bayer$273
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$3,59896%
  • Education$1684%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,988 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$214,383
Medicare patients
442
Services billed
2,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol166$220,516
JardianceEmpagliflozin30$46,909
KerendiaFinerenone20$36,990
LokelmaSodium Zirconium Cyclosilicate16$16,578
Sevelamer Carbonate31$12,137
VeltassaPatiromer Calcium Sorbitex11$11,123
Calcitriol89$1,931
Nifedipine ErNifedipine30$1,542
Losartan Potassium119$1,225
Hydralazine Hcl47$874
Valsartan25$722
Bumetanide13$605
Potassium Chloride30$601
Furosemide90$547
Amlodipine Besylate52$505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$561$237,094182 claims
Boehringer IngelheimJardiance$43$46,90930 claims
BayerKerendia$273$36,99020 claims
ANI Pharmaceuticals, Inc.Valsartan$71$72225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 756 nephrology providers in Florida.

Other nephrology in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →